Champions Oncology EV/EBIT CSBR

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2019.

Today, Oct 23, 2026: n/m; an operating loss
Last meaningful: 34.0×; Mar 2026
7-year median: 184×
7-year range: 12.2× to 401×
Peer median: 7.8×

Champions Oncology has no meaningful EV/EBIT today: it made an operating loss of $1M over the last twelve months.

It was last meaningful in Mar 2026, at 34.0×.

On the days it had one over the last 7 years, its median was 184×, from 12.2× in May 2025 to 401× in Jul 2022.

EV/EBIT over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	34.0×	33.7×	43.3×
2025	41.1×	12.2×	42.7×
2024	n/m a value too high to mean anything
2023	207×	184×	213×
2022	208×	150×	401×
2021	256×	246×	390×
2020	n/m a value too high to mean anything
2019	248×	220×	254×

Against its peers

Companies in Healthcare nearest Champions Oncology's size, closest first, today.

Company	EV/EBIT
CSBRChampions Oncology	n/m
SPROSpero Therapeutics	2.1×
LFVNLifevantage	9.6×
APTAlpha Pro Tech	8.2×
ATNMActinium Pharmaceuticals	1.2×
ICCCImmucell	14.2×
KEQUKewaunee Scientific	7.2×
NEPHNephros	20.5×
PDEXPro DEX	16.0×
PLXProtalix BioTherapeutics	7.5×
NATRNatures Sunshine Products	5.2×
Peer median	7.8×

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Champions Oncology

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.